Trevi Therapeutics (TRVI) Accumulated Depreciation (2018 - 2025)
Trevi Therapeutics (TRVI) posted quarterly Accumulated Depreciation of $359000.0 for Q4 2025, up 57.46% year-over-year from $228000.0 in Q4 2024, and up 57.46% quarter-over-quarter from $228000.0 in Q4 2024.
Trevi Therapeutics (TRVI) Accumulated Depreciation (2018 - 2025) Analysis & Trends
Trevi Therapeutics' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $359000.0 for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 57.46% year-over-year to $359000.0; the TTM figure through Dec 2025 stood at $359000.0 (up 57.46% YoY), while the FY2025 annual figure was $359000.0, up 57.46% from the prior year.
- Accumulated Depreciation for Q4 2025 stood at $359000.0, up from $228000.0 in the prior quarter.
- The five-year high for Accumulated Depreciation was $359000.0 in Q4 2025, with the low at $134000.0 in Q4 2023.
- The 5-year median for Accumulated Depreciation is $225000.0 (2022), against an average of $225600.0.
- The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation sank 40.44% in 2023, then jumped 70.15% in 2024.
- Trevi Therapeutics' Accumulated Depreciation stood at $182000.0 in 2021, then grew by 23.63% to $225000.0 in 2022, then tumbled by 40.44% to $134000.0 in 2023, then surged by 70.15% to $228000.0 in 2024, then soared by 57.46% to $359000.0 in 2025.
- Business Quant data shows TRVI's Accumulated Depreciation at $359000.0 in Q4 2025, $228000.0 in Q4 2024, and $134000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Dec 31, 2022 | 225,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Dec 31, 2020 | 132,000.00 |
| Dec 31, 2019 | 85,000.00 |
| Dec 31, 2018 | 46,000.00 |